VIR

Vir Biotechnology (VIR)

About Vir Biotechnology (VIR)

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Details

Daily high

$7.22

Daily low

$6.89

Price at open

$7.15

52 Week High

$14.45

52 Week Low

$6.56

Market cap

953.1M

Dividend yield

0.00%

Volume

1.7M

Avg. volume

1.4M

P/E ratio

-1.82

Vir Biotechnology News